Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04506983 Suspended - Clinical trials for Hepatocellular Carcinoma

GPC3-CAR-T Cells for the Hepatocellular Carcinoma

Start date: June 10, 2022
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.

NCT ID: NCT04327700 Suspended - Clinical trials for Hepatocellular Carcinoma

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Start date: January 26, 2021
Phase: Phase 2
Study type: Interventional

The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular carcinoma who have received any first line systemic therapy either standard of care Sorafenib or Lenvatinib or any experimental therapy. Patients who have received any treatment that includes either electromagnetic fields or Regorafenib will be excluded.

NCT ID: NCT03990974 Suspended - Clinical trials for Hepatocellular Carcinoma

Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection

HCC
Start date: September 2020
Phase: Phase 3
Study type: Interventional

This trial is a multi-center, double-blinded, randomized (1:1) clinical trial. The aim is to compare the postoperative infection rate between the 3 days postoperative AMP group and the placebo group in HCC patients undergoing hepatectomy.

NCT ID: NCT02935478 Suspended - Obesity Clinical Trials

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

Start date: October 18, 2017
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving them of the best option for cure from HCC. Recent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with cirrhosis and HCC who are not transplant candidates due to morbid obesity, leads to clinically significant weight loss with eligibility for liver transplantation.

NCT ID: NCT02026362 Suspended - Clinical trials for Hepatocellular Carcinoma

Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

HCC DC CTL
Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.